News Archive Navigation
icon
Showing 113 results
October 2017
-
Media ReleaseNovartis partners with medical experts, patient group to raise awareness on psoriasisIn observance of World Psoriasis Day on October 29, 2017 Novartis Healthcare Philippines in partnership with the Philippine Dermatological Society (PDS), Philippine Rheumatology Association (PRA),…
-
Media ReleaseNovartis, Philippine College of Chest Physicians launch COPD awareness campaignChronic Obstructive Pulmonary Disease (COPD), the seventh leading cause of death in the Philippines, has a destructive impact on patients’ function and quality of life, and increases the risk of…
July 2017
-
Media ReleaseNovartis partners with local diabetes experts to enhance primary care physicians’ skills in diabetes diagnosis and managementType 2 diabetes mellitus (T2DM) is one of the leading causes of sickness and death in the Philippines. To help address this problem, Novartis Healthcare Philippines, the American Association of…
-
Media ReleaseDOH, Novartis gather stakeholders to achieve zero leprosy transmission in PHThe Stakeholders Meeting on Leprosy aims to galvanize efforts to achieve zero transmission of leprosy in the Philippines. It was held on July 5-6, 2017 at the Manila Diamond Hotel, with the theme “…
June 2017
-
Media ReleaseIncreased awareness on organ donation key to saving lives of Filipinos requiring kidney transplantationFor many patients with end-stage renal disease (ESRD), the only option for survival is a kidney transplant. Unfortunately in the Philippines, the number of living and deceased kidney donors…
-
Media ReleaseNovartis’ secukinumab shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 yearsSecukinumab is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) Additional data show rapid and…
March 2017
-
Media ReleaseNovartis’ secukinumab is first and only IL-17A inhibitor to potentially modify the course of psoriasisNew data suggests that disease modification with secukinumab may be achievable for around 20% of patients following one year of treatment1 Patients with longer disease duration before treatment…
-
Media ReleaseNovartis partners with ADB, Swiss Embassy to hold forum on achieving universal health coverage in developing countriesSwiss and Filipino stakeholders in the healthcare sector gather at the Asian Development Bank (ADB) headquarters in Mandaluyong City to present and learn from innovative health policies and…
-
Media ReleaseNovartis global survey shows 85% fear blindness, but only 33% have regular eye examinationSurvey shows 85% of respondents are most afraid to lose eye sight of their five senses, 87% of respondents believe regular eye exams are important but only 33% reported visiting annual screenings…
-
Media ReleaseNovartis partners with Philippine Glaucoma Society to help prevent blindness, promote regular eye examsIn line with World Glaucoma Week, Novartis signed a Memorandum of Agreement with the Philippine Glaucoma Society to promote awareness on glaucoma and the importance of regular eye examinations, as…
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- › Next page